MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions with unmet medical needs, particularly Wilson disease.
Founded by Dr. Michal Shoshan (CEO), with an extensive background in inorganic medicinal chemistry, metaLead leverages its expertise in metal-binding peptides and chelation.
The company has developed a cutting-edge drug development platform designed to identify and optimize short novel peptidic therapies targeting metal-related pathologies. After showcasing the platform’s capabilities on lead poisoning, metaLead is now focusing on the preclinical development of best-in-class treatments for Wilson disease, a rare genetic disorder causing the toxic accumulation of copper in the liver and brain.
metaLead is poised to advance its research pipeline, which includes programs aimed at addressing metal overload disorders and beyond.
We are pleased to welcome metaLead to our portfolio!
